Dr. Meier-Davis joined Apricus as Vice President of Safety in February 2012, managing the pharmacovigilance activities and nonclinical/clinical safety programs for the company. Dr. Meier-Davis has more than 15 years of wide-ranging experience in the pharmaceutical industry having actively participated in transdermal, anti-infective, Alzheimer's disease, chemotherapy and cardiovascular drug development programs. Previously, Dr. Meier-Davis was the Director of Nonclinical at Teikoku Pharma USA and Fibrogen and held Senior Scientist positions at Theravance and Alza. Dr. Meier-Davis has authored many nonclinical and clinical sections of INDs, one NDA, several peer-reviewed journal articles, in addition to holding five patents.

Dr. Meier-Davis received her Doctor of Veterinary Medicine (DVM) degree from the University of Wisconsin at Madison and her PhD in molecular pharmacology from the Stanford University School of Medicine. Dr. Meier-Davis is board-certified in toxicology from the American Board of Toxicology (DABT) and certified in regulatory affairs (RAC) for both medical devices and pharmaceuticals.